MK‐2206 is an allosteric inhibitor of AKT and resulted in a higher pathologic complete response rate in HR‐negative and HER2‐positive breast cancer when combined with standard neoadjuvant therapy (NCT01042379).364. Here, AKT1 is linked to breast carcinoma.